Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter
Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.
You may also be interested in...
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.
Professional Detailing, Inc. gains U.S. marketing rights for the ACE inhibitor benazepril and Lotensin HCT (benazepril/hydrochlorothiazide) through 2003. PDI will also co-promote Lotrel (amlodipine/benazepril). Novartis will continue to manufacture the three products
Novartis' chronic myeloid leukemia therapy Gleevec will be available in pharmacies by the time oncologists return from the American Society of Clinical Oncology May 12-15 meeting.